nach oben

Current Oncology Reports

Erschienen in:

13.09.2023

Chemotherapy-Induced Peripheral Neuropathy: Diagnosis, Agents, General Clinical Presentation, and Treatments

verfasst von: Diana Molinares, Sara Kurtevski, Yingrong Zhu

Erschienen in: Current Oncology Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review aims to discuss pathophysiology, diagnosis, clinical presentation, and treatment of chemotherapy-induced peripheral neuropathy. Agent-specific presentation and pathophysiology is also being discussed.

Recent Findings

As new systemic oncological treatments continue to be developed, the number of cancer survivors continues to grow. Survivors are living longer with the long-term side effects of oncological treatments. We reviewed the pathophysiology of agent-specific chemotherapy-induced peripheral neuropathy and the updates in its treatment and preventative tools.

Summary

Chemotherapy-induced peripheral neuropathy is a debilitating long-term side effect that often impairs cancer survivors’ function and quality of life. The increasing life expectancy of cancer survivors has resulted in increased prevalence of this condition. Understanding its intricacies can provide physicians with better treatment tools and research opportunities to develop or identify new therapeutic agents.

• Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: a review. Semin Oncol. 2021;48(3):193–207. https://doi.org/10.1053/j.seminoncol.2021.09.004. This article reviews the impact of CIPN in survivors’ quality of life and the role of cancer rehabilitation medicine. The authors reviewed the treatment options and rehabilitation interventions for patients with CIPN.

Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772–81. https://doi.org/10.1002/ana.24951.CrossRefPubMedPubMedCentral

• Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, Mak T, Marshall A, Frank B, Malik RA, Alam U. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther. 2021;9(2):385–450. https://doi.org/10.1007/s40487-021-00168-y. This article highlights the epidemiology of CIPN as well as preventative treatments. Authors highlight the importance of identifying at risk patients and further investigate into preventive measures as well as new symptomatic treatments.CrossRefPubMedPubMedCentral

Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D. Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review. Front Pharmacol. 2017;8 https://doi.org/10.3389/fphar.2017.00086.

• Tofthagen, C. S., Cheville, A. L., & Loprinzi, C. L. (2020). The physical consequences of chemotherapy-induced peripheral neuropathy. Curr Oncol Rep, 22(5). https://doi.org/10.1007/s11912-020-00903-0. This article reviews the effects of CIPN in survivors’ physical function and the long-term impact in their wellbeing. The authors discussed the evidence-based interventions currently available to treat this condition.

Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451.CrossRefPubMedPubMedCentral

Timmins HC, Li T, Huynh W, Kiernan MC, Baron-Hay S, Boyle F, Goldstein D, Park SB. Electrophysiological and phenotypic profiles of taxane-induced neuropathy. Clin Neurophysiol. 2020;131(8):1979–85. https://doi.org/10.1016/j.clinph.2020.02.028.CrossRefPubMed

Iżycki D, Niezgoda AA, Kaźmierczak M, Piorunek T, Iżycka N, Karaszewska B, Nowak-Markwitz E. Chemotherapy-induced peripheral neuropathy — diagnosis, evolution and treatment. Ginekologia Polska. 2016;87(7):516–21. https://doi.org/10.5603/gp.2016.0036.CrossRefPubMed

Argyriou A, Kyritsis A, Makatsoris T, Kalofonos H. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014;6:135–47. https://doi.org/10.2147/cmar.s44261.CrossRefPubMedPubMedCentral

10.

van Haren F, van den Heuvel S, Ligtenberg M, Vissers K, Steegers M. Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes. Cancer Rep. 2021;5(10) https://doi.org/10.1002/cnr2.1577.

11.

Staff NP, Cavaletti G, Islam B, Lustberg M, Psimaras D, Tamburin S. Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019;24(S2) https://doi.org/10.1111/jns.12335.

12.

Sałat K. Chemotherapy-induced peripheral neuropathy—part 2: focus on the prevention of oxaliplatin-induced neurotoxicity. Pharmacol Rep. 2020;72(3):508–27. https://doi.org/10.1007/s43440-020-00106-1.CrossRefPubMedPubMedCentral

13.

Li T, Mizrahi D, Goldstein D, Kiernan MC, Park SB. Chemotherapy and peripheral neuropathy. Neurol Sci. 2021;42(10):4109–21. https://doi.org/10.1007/s10072-021-05576-6.CrossRefPubMed

14.

Timmins HC, Li T, Kiernan MC, Baron-Hay S, Marx G, Boyle F, Goldstein D, Park SB. Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Supp Care Cancer. 2020;28(9):4459–66. https://doi.org/10.1007/s00520-020-05299-y.CrossRef

15.

Jongen JL, Broijl A, Sonneveld P. Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neuro-Oncol. 2014;121(2):229–37. https://doi.org/10.1007/s11060-014-1632-x.CrossRef

16.

Madsen ML, Due H, Ejskjær N, Jensen P, Madsen J, Dybkær K. Aspects of vincristine-induced neuropathy in hematologic malignancies: a systematic review. Cancer Chemother Pharmacol. 2019;84(3):471–85. https://doi.org/10.1007/s00280-019-03884-5.CrossRefPubMedPubMedCentral

17.

Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81(12):1372–3. https://doi.org/10.1136/jnnp.2008.144964.CrossRefPubMed

18.

Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag. 2007;3(6):833–44.PubMedPubMedCentral

19.

Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, et al. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer. 2016;24(3):1071–8. https://doi.org/10.1007/s00520-015-2876-5.CrossRefPubMed

20.

Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol. 2020;38(28):3325–48. https://doi.org/10.1200/jco.20.01399.CrossRefPubMed

21.

Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67. https://doi.org/10.1001/jama.2013.2813.CrossRefPubMedPubMedCentral

22.

Chow R, Novosel M, So O, et al. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis. BMJ Support Palliat Care. 2022; https://doi.org/10.1136/spcare-2022-003815.

23.

Rodrigues-Amorim D, Olivares JM, Spuch C, Rivera-Baltanas T. A systematic review of efficacy, safety, and tolerability of duloxetine. Front Psychiatry. 2020;11:554899. https://doi.org/10.3389/fpsyt.2020.554899.CrossRefPubMedPubMedCentral

24.

Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5. https://doi.org/10.1093/annonc/mdr045.CrossRefPubMed

25.

Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;(7):CD008242. https://doi.org/10.1002/14651858.CD008242.pub3.

26.

Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 2008;35(1):31–9. https://doi.org/10.1016/j.jpainsymman.2007.02.043.CrossRefPubMed

27.

Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ, Soori GS, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain. 2002;98(1-2):195–203. https://doi.org/10.1016/s0304-3959(02)00047-7.CrossRefPubMed

28.

Kautio AL, Haanpaa M, Leminen A, Kalso E, Kautiainen H, Saarto T. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Res. 2009;29(7):2601–6.

29.

Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem. 1996;271(10):5768–76. https://doi.org/10.1074/jbc.271.10.5768.CrossRefPubMed

30.

Wiffen PJ, Derry S, Bell RF, Rice AS, Tolle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:CD007938. https://doi.org/10.1002/14651858.CD007938.pub4.CrossRefPubMed

31.

Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110(9):2110–8. https://doi.org/10.1002/cncr.23008.CrossRefPubMed

32.

Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010;30(7):2927–33.PubMed

33.

de Andrade DC, Jacobsen Teixeira M, Galhardoni R, Ferreira KSL, Braz Mileno P, Scisci N, et al. Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial. Oncologist. 2017;22(10):1154–e105. https://doi.org/10.1634/theoncologist.2017-0235.CrossRefPubMedPubMedCentral

34.

Hamity MV, White SR, Walder RY, Schmidt MS, Brenner C, Hammond DL. Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Pain. 2017;158(5):962–72. https://doi.org/10.1097/j.pain.0000000000000862.CrossRefPubMed

35.

Wiernik PH, Yeap B, Vogl SE, Kaplan BH, Comis RL, Falkson G, et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest. 1992;10(1):1–9. https://doi.org/10.3109/07357909209032783.CrossRefPubMed

36.

Solomon LR. Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain. Support Care Cancer. 2016;24(8):3489–94. https://doi.org/10.1007/s00520-016-3175-5.CrossRefPubMed

37.

Schloss JM, Colosimo M, Airey C, Vitetta L. Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. Support Care Cancer. 2015;23(7):1843–50. https://doi.org/10.1007/s00520-015-2725-6.CrossRefPubMed

38.

Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 1995;13(1):26–32. https://doi.org/10.1200/JCO.1995.13.1.26.CrossRefPubMed

39.

Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20(16):3478–83. https://doi.org/10.1200/JCO.2002.07.061.CrossRefPubMed

40.

Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, et al. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014;120(12):1890–7. https://doi.org/10.1002/cncr.28654.CrossRefPubMed

41.

Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47(1):166–73. https://doi.org/10.1016/j.jpainsymman.2013.02.018.CrossRefPubMed

42.

Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713–37. https://doi.org/10.1016/j.nurt.2009.08.002.CrossRefPubMedPubMedCentral

43.

Lynch ME, Clark AJ, Sawynok J, Sullivan MJ. Topical amitriptyline and ketamine in neuropathic pain syndromes: an open-label study. J Pain. 2005;6(10):644–9. https://doi.org/10.1016/j.jpain.2005.04.008.CrossRefPubMed

44.

Gewandter JS, Mohile SG, Heckler CE, Ryan JL, Kirshner JJ, Flynn PJ, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22(7):1807–14. https://doi.org/10.1007/s00520-014-2158-7.CrossRefPubMedPubMedCentral

45.

Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502. https://doi.org/10.1093/bja/aer260.CrossRefPubMedPubMedCentral

46.

Anand P, Elsafa E, Privitera R, Naidoo K, Yiangou Y, Donatien P, et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res. 2019;12:2039–52. https://doi.org/10.2147/JPR.S213912.CrossRefPubMedPubMedCentral

47.

Bailey AG, Brown JN, Hammond JM. Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: a systematic review. J Oncol Pharm Pract. 2021;27(1):156–64. https://doi.org/10.1177/1078155220959431.CrossRefPubMed

48.

Izgu N, Metin ZG, Karadas C, Ozdemir L, Cetin N, Demirci U. Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: an assessor-blinded randomized controlled trial. Eur J Oncol Nurs. 2019;40:36–43. https://doi.org/10.1016/j.ejon.2019.03.002.CrossRefPubMed

49.

Kurt S, Can G. Reflexology in the management of chemotherapy induced peripheral neuropathy: a pilot randomized controlled trial. Eur J Oncol Nurs. 2018;32:12–9. https://doi.org/10.1016/j.ejon.2017.11.001.CrossRefPubMed

50.

Ernst E, Lee MS. Acupuncture for palliative and supportive cancer care: a systematic review of systematic reviews. J Pain Symptom Manage. 2010;40(1):e3–5. https://doi.org/10.1016/j.jpainsymman.2010.03.010.CrossRefPubMed

51.

Dimitrova A, Murchison C, Oken B. Acupuncture for the treatment of peripheral neuropathy: a systematic review and meta-analysis. J Altern Complement Med. 2017;23(3):164–79. https://doi.org/10.1089/acm.2016.0155.CrossRefPubMedPubMedCentral

52.

Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, et al. Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat. 2016;156(3):453–64. https://doi.org/10.1007/s10549-016-3759-2.CrossRefPubMedPubMedCentral

53.

Han X, Wang L, Shi H, Zheng G, He J, Wu W, et al. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. BMC Cancer. 2017;17(1):40. https://doi.org/10.1186/s12885-016-3037-z.CrossRefPubMedPubMedCentral

54.

Lu W, Giobbie-Hurder A, Freedman RA, Shin IH, Lin NU, Partridge AH, et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: a randomized controlled pilot trial. Oncologist. 2020;25(4):310–8. https://doi.org/10.1634/theoncologist.2019-0489.CrossRefPubMed

55.

Huang CC, Ho TJ, Ho HY, Chen PY, Tu CH, Huang YC, et al. Acupuncture relieved chemotherapy-induced peripheral neuropathy in patients with breast cancer: a pilot randomized sham-controlled trial. J Clin Med. 2021;10(16) https://doi.org/10.3390/jcm10163694.

56.

Rostock M, Jaroslawski K, Guethlin C, Ludtke R, Schroder S, Bartsch HH. Chemotherapy-induced peripheral neuropathy in cancer patients: a four-arm randomized trial on the effectiveness of electroacupuncture. Evid Based Complement Alternat Med. 2013;2013:349653. https://doi.org/10.1155/2013/349653.CrossRefPubMedPubMedCentral

57.

Lu W, Rosenthal DS. Recent advances in oncology acupuncture and safety considerations in practice. Curr Treat Options Oncol. 2010;11(3-4):141–6. https://doi.org/10.1007/s11864-010-0126-0.CrossRefPubMedPubMedCentral

58.

D'Souza RS, Her YF, Jin MY, Morsi M, Abd-Elsayed A. Neuromodulation therapy for chemotherapy-induced peripheral neuropathy: a systematic review. Biomedicines. 2022;10(8) https://doi.org/10.3390/biomedicines10081909.

59.

Ege E, Briggi D, Mach S, Huh BK, Javed S. Dorsal root ganglion stimulation for chemotherapy-induced peripheral neuropathy. Pain Pract. 2023; https://doi.org/10.1111/papr.13259.

60.

Gewandter JS, Chaudari J, Ibegbu C, Kitt R, Serventi J, Burke J, et al. Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Support Care Cancer. 2019;27(5):1765–74. https://doi.org/10.1007/s00520-018-4424-6.CrossRefPubMed

61.

Loprinzi C, Le-Rademacher JG, Majithia N, McMurray RP, O'Neill CR, Bendel MA, et al. Scrambler therapy for chemotherapy neuropathy: a randomized phase II pilot trial. Support Care Cancer. 2020;28(3):1183–97. https://doi.org/10.1007/s00520-019-04881-3.CrossRefPubMed

62.

Smith TJ, Razzak AR, Blackford AL, Ensminger J, Saiki C, Longo-Schoberlein D, et al. A pilot randomized sham-controlled trial of MC5-A scrambler therapy in the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN). J Palliat Care. 2020;35(1):53–8. https://doi.org/10.1177/0825859719827589.CrossRefPubMed

Titel: Chemotherapy-Induced Peripheral Neuropathy: Diagnosis, Agents, General Clinical Presentation, and Treatments
verfasst von: Diana Molinares
Sara Kurtevski
Yingrong Zhu
Publikationsdatum: 13.09.2023
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 11/2023
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01449-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Chemotherapy-Induced Peripheral Neuropathy: Diagnosis, Agents, General Clinical Presentation, and Treatments

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2023

Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives

Novel Therapeutic Options for Small Cell Lung Cancer

Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma

Immune-Related Adverse Events in Patients with Lung Cancer

Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts

Exercise as Medicine in Cardio-Oncology: Reducing Health Disparities in Hispanic and Latina Breast Cancer Survivors

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie